Cargando…

BCR-ABL1 positive B-ALL can undergo T-cell lineage shift to become CD19 negative T-ALL

Detalles Bibliográficos
Autores principales:	De Bie, Jolien, Demeyer, Sofie, Gielen, Olga, Segers, Heidi, Michaux, Lucienne, Vandenberghe, Peter, Boeckx, Nancy, Uyttebroeck, Anne, Cools, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745988/ https://www.ncbi.nlm.nih.gov/pubmed/31723770 http://dx.doi.org/10.1097/HS9.0000000000000042

Ejemplares similares

Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia
por: De Bie, Jolien, et al.
Publicado: (2018)

Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing
por: Meyers, Sarah, et al.
Publicado: (2022)

Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping
por: Rack, Katrina, et al.
Publicado: (2022)

t(1;7;22)(p13;q21;q13) is a novel 3-way variant of t(1;22)(p13;q13) neonatal acute megakaryoblastic leukemia: A case report
por: Messiaen, Julie, et al.
Publicado: (2023)

The suppressive functions of Rora in B lineage cell proliferation and BCR/ABL1-induced B-ALL pathogenesis
por: Li, Ning, et al.
Publicado: (2022)

Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia
por: Verbeke, Delphine, et al.
Publicado: (2019)

An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement
por: Lizcova, Libuse, et al.
Publicado: (2014)

Inflammation accelerates BCR-ABL1(+) B-ALL development through upregulation of AID
por: Zhang, Ping, et al.
Publicado: (2022)

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL
por: Rix, Uwe, et al.
Publicado: (2013)

BCR‐ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph(+) ALL
por: Cao, Wen‐bin, et al.
Publicado: (2018)

Susceptibility Of Ph-Positive All To Tki Therapy Associated With Bcr-Abl Rearrangement Patterns: A Retrospective Analysis
por: Jing, Yu, et al.
Publicado: (2014)

Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1(+) pre–B ALL
por: Schjerven, Hilde, et al.
Publicado: (2017)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Chimeric JAK2 Kinases Trigger Non-uniform Changes of Cellular Metabolism in BCR-ABL1-like Childhood ALL
por: Lukes, Julius, et al.
Publicado: (2023)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL
por: Lin, Xiaojing, et al.
Publicado: (2016)

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system
por: Bornschein, S, et al.
Publicado: (2018)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Prognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy
por: Libura, Marta, et al.
Publicado: (2023)

Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
por: Mizuta, S, et al.
Publicado: (2012)

A paradigm shift: lineage switch from T-ALL to B/myeloid MPAL
por: Rath, Asish, et al.
Publicado: (2021)

A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1(−) pre-B-ALL
por: Wang, Zhihua, et al.
Publicado: (2020)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia
por: Thielemans, Naomi, et al.
Publicado: (2022)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia
por: Vanden Bempt, Marlies, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f883arn0pniktgbssvcqqqe05b